Barclays Remains Bullish on Vertex (VRTX); Upside to Phase I Data

May 25, 2012 1:40 PM EDT
Get Alerts VRTX Hot Sheet
Price: $81.92 -1.5%

Rating Summary:
    24 Buy, 17 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade VRTX Now!
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Vertex (NASDAQ: VRTX) price target of $77.00.

Analyst, Ying Huang, said, "We remain bullish as we see upside from Phase I data of the Alios nucleotide HCV polymerase inhibitors (nucs). Next key catalyst lies in the data of Kalydeco/VX-809 in cystic fibrosis patients with heterozygous F508del mutation in July."

Huang thinks Vertex's nucs are similar to the Gilead (Nasdaq: GILD) / Bristol Myers (NYSE: BMY) nucs in structure.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $64.09 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment